King's College London

Funding Information: A.H.Y. has delivered paid lectures or sat on the advisory boards for the following companies with drugs used in affective and related disorders: AstraZeneca, Eli Lilly, Lundbeck, Sunovion, Servier, LivaNova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma. He is a consultant to LivaNova and Johnson & Johnson; has received honoraria for attending advisory boards and presenting talks at meetings organised by LivaNova; and is Principal Investigator on the following: the Restore-Life VNS registry study funded by LivaNova; ‘An open-label, long-term, safety and efficacy study of intranasal esketamine in treatment-resistant depression’ (ESKETINTRD3004); ‘The effects of psilocybin on cognitive function in healthy participants’ (IRAS ID 246135); and ‘The safety and efficacy of psilocybin in participants with treatment-resistant depression (P-TRD)’ (NCT03775200). He receives or has received grant funding from: NIMH (USA); CIHR (Canada); NARSAD (USA); Stanley Medical Research Institute (USA); MRC (UK); Wellcome Trust (UK); Royal College of Physicians (Edin); BMA (UK); UBC-VGH Foundation (Canada); WEDC (Canada); CCS Depression Research Fund (Canada); MSFHR (Canada); NIHR (UK); and Janssen (UK). Publisher Copyright: © The Author(s), 2022. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists.